Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its innovative oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. For more information, visit the company’s Web site at www.pvct.com.

Let us hear your thoughts below: